カテゴリー： 世界, 医療/バイオ, Grand View Research

世界の抗体受託開発・製造機関市場2023-2030：製品別、供給源別、治療領域別（腫瘍学、神経学、心臓病学）、エンドユーザー別、地域別

【英語タイトル】Antibody Contract Development & Manufacturing Organization Market Size, Share & Trends Analysis Report By Product, By Source, By Therapeutic Area (Oncology, Neurology, Cardiology), By End-use, By Region, And Segment Forecasts, 2023 - 2030

Grand View Researchが出版した調査資料（GRV23NOV036）・商品コード：GRV23NOV036
・発行会社（調査会社）：Grand View Research
・発行日：2023年9月
・ページ数：175
・レポート言語：英語
・レポート形式：PDF
・納品方法：Eメール（受注後3営業日）
・調査対象地域：グローバル
・産業分野：製薬
◆販売価格オプション（消費税別）
Single UserUSD5,950 ⇒換算￥904,400見積依頼/購入/質問フォーム
Multi User/Five UserUSD6,950 ⇒換算￥1,056,400見積依頼/購入/質問フォーム
Global/corporate LicenseUSD8,950 ⇒換算￥1,360,400見積依頼/購入/質問フォーム
※販売価格オプションの説明
※お支払金額：換算金額（日本円）＋消費税
※納期：即日〜2営業日（3日以上かかる場合は別途表記又はご連絡）
※お支払方法：納品日＋5日以内に請求書を発行・送付（請求書発行日より2ヶ月以内に銀行振込、振込先：三菱UFJ銀行/H&Iグローバルリサーチ株式会社、支払期限と方法は調整可能）
❖ レポートの概要 ❖

抗体受託開発・製造機関市場の成長と動向
Grand View Research, Inc.の最新レポートによると、世界の抗体受託開発・製造機関市場は2023年から2030年にかけて年平均成長率14.0%で拡大し、2030年には584億ドルに達する見込みです。新規抗体治療薬の発見に関する研究開発活動の増加、癌患者の増加、開発・製造受託機関（CDMO）とバイオ製薬企業間の協力関係の高まりが、抗体受託開発・製造機関市場の成長を促進する主な要因です。

抗体は薬物療法であり、特に癌治療に用いられます。これらの抗体は、体内の健康な細胞に影響を与えず、薬剤の治療指数を向上させます。これらは、がん治療における抗体の需要が高い2つの主な理由です。これらの要因が、臨床研究における抗体薬物複合体（ADC）などの抗体タイプの開発を支えています。

がん治療における抗体の効率の高さから、バイオ医薬品企業は抗体関連の研究を行うために多額の資金援助を受けています。例えば、2022年10月、Mablink Bioscienceは、がん治療用の抗体ADCパイプラインを構築するため、シリーズA資金調達から3100万米ドルを調達しました。同様に、2021年7月には、ProfoundBio社が抗体ADCパイプラインの開発を加速させるため、投資家から5,500万米ドルを受け取りました。したがって、がん治療に関連する新規治療薬を開発するためのバイオ医薬品企業による取り組みの増加は、市場の成長を支える主な要因の1つです。

COVID-19の流行は市場に大きな影響を与えました。しかし、いくつかの企業は、パンデミックの影響を緩和し、それによって売上収益の回復を目撃するために、パートナーシップ、合併、買収などの組織内戦略的イニシアチブを採用しました。さらに、ウクライナとロシア間の地政学的戦争は抗体受託開発・製造機関市場にマイナスの影響を与えています。これは米国など特定の国に大きな影響を与えており、そのため世界市場全体の収益は2022年中に緩やかに落ち込んでいます。

抗体受託開発・製造機関市場レポートハイライト

- モノクローナル抗体セグメントは2022年に67.6%の最大シェアを占めました。このセグメントは、抗がんベースのモノクローナル抗体治療薬に対する需要の高まりが原動力となっており、抗体治療薬全体の大部分を占めています。

- ソース別では、哺乳類セグメントが2022年に58.5%の最大シェアを占めました。このセグメントのシェアが高い主な理由は、哺乳類抗体治療薬全体でアウトソーシングの割合が増加しているためです。したがって、CDMOは自社生産よりも比較的低コストでこれらの製造サービスを提供し、市場での大きなセグメントシェアを支えています。

- 免疫介在性疾患分野は、予測期間中に最も速いCAGR 14.6%を記録すると予測されています。これは、免疫介在性疾患の治療における新規抗体の発見を目的とした臨床試験の割合が増加しているためです。

- バイオ医薬品企業は、2023年から2030年にかけて最も速いCAGR 14.3%を記録すると予測されています。これは、新規抗体治療薬の生産に注力するバイオ医薬品企業の増加によるもので、予測期間中の有利な成長を支えています。

- アジア太平洋地域は、予測期間中に14.2%の高いCAGRを記録すると予測されています。高い成長の主な要因は、インドや中国などのアジア諸国であり、生産コストが欧米諸国よりも比較的低いため、この地域全体でより多くの顧客層を惹きつけ、この地域の成長を支えています。

第1章 調査方法・範囲
第2章 エグゼクティブサマリー
第3章 世界の抗体受託開発・製造機関市場変数・傾向・範囲
第4章 世界の抗体受託開発・製造機関市場：製品別予測・傾向分析
第5章 世界の抗体受託開発・製造機関市場：供給源別予測・傾向分析
第6章 世界の抗体受託開発・製造機関市場：治療領域別予測・傾向分析
第7章 世界の抗体受託開発・製造機関市場：エンドユーザー別予測・傾向分析
第8章 世界の抗体受託開発・製造機関市場：地域別予測・傾向分析
第9章 競争状況

グローバル市場調査レポート販売サイトのwww.marketreport.jpです。

❖ レポートの目次 ❖

Table of Contents

Chapter 1. Research Methodology and Scope
1.1. Market Segmentation & Scope
1.1.1. Segment Definitions
1.1.2. Product
1.1.3. Source
1.1.4. Therapeutic Area
1.1.5. End Use
1.2. Regional Scope
1.3. Estimates And Forecast Timeline
1.4. Objectives
1.4.1. Objective-1
1.4.2. Objective-2
1.4.3. Objective-3
1.5. Research Methodology
1.6. Information Procurement
1.6.1. Purchased Database
1.6.2. GVR’s Internal Database
1.6.3. Secondary Sources
1.6.4. Primary Research
1.7. Information Or Data Analysis
1.7.1. Data Analysis Models
1.8. Market Formulation & Validation
1.9. Model Details
1.9.1. Commodity Flow Analysis
1.9.2. Parent Market Analysis
1.10. List Of Secondary Sources
1.11. List Of Abbreviations
Chapter 2. Executive Summary
2.1. Market Outlook
2.2. Segment Outlook
2.3. Competitive Insights
Chapter 3. Antibody CDMO Market Variables, Trends & Scope
3.1. Market Lineage Outlook
3.1.1. Parent Market Outlook
3.1.2. Related/Ancillary Market Outlook
3.2. Market Dynamics
3.2.1. Market Driver Analysis
3.2.1.1. Increasing Rate of Clinical Research to Boost Demand for Antibody CDMO Services
3.2.1.2. Rising Incidence of Cancer
3.2.1.3. High Cost of Manufacturing Antibodies and Challenges Associated with Manufacturing Contributing to Demand For Outsourcing Services
3.2.2. Market Restraint Analysis
3.2.2.1. Quality Issues While Outsourcing
3.2.2.2. Limited Outsourcing Opted by Big Biopharma Companies
3.3. Antibody CDMO Market Analysis Tools
3.3.1. Industry Analysis – Porter’s
3.3.1.1. Supplier Power
3.3.1.2. Buyer Power
3.3.1.3. Substitution Threat
3.3.1.4. Threat Of New Entrant
3.3.1.5. Competitive Rivalry
3.3.2. PESTEL Analysis
3.3.3. COVID-19 Impact Analysis
3.3.4. Clinical Trial Volume Analysis for Antibody Research, (2022)
3.3.5. Regulatory Landscape:
3.3.5.1. U.S.
3.3.5.2. Europe
3.3.5.3. Asia Pacific
3.3.5.4. Rest of the World
Chapter 4. Antibody CDMO Market: Product Estimates & Trend Analysis
4.1. Antibody CDMO Market, By Product: Segment Dashboard
4.2. Antibody CDMO Market, By Product: Movement Analysis
4.3. Antibody CDMO Market Estimates & Forecasts, By Product, 2018 – 2030
4.3.1. Monoclonal Antibodies
4.3.1.1. Monoclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
4.3.2. Polyclonal Antibodies
4.3.2.1. Polyclonal Antibodies Antibody CDMO Market, 2018 to 2030, (USD Million)
4.3.3. Others
4.3.3.1. Others Antibody CDMO Market, 2018 to 2030, (USD Million)
Chapter 5. Antibody CDMO Market: Source Estimates & Trend Analysis
5.1. Antibody CDMO Market, By Source: Segment Dashboard
5.2. Antibody CDMO Market, By Source: Movement Analysis
5.3. Antibody CDMO Market Estimates & Forecasts, By Source, 2018 – 2030
5.3.1. Mammalian
5.3.1.1. Mammalian Antibody CDMO Market, 2018 to 2030 (USD Million)
5.3.2. Microbial
5.3.2.1. Microbial Antibody CDMO Market, 2018 to 2030, (USD Million)
Chapter 6. Antibody CDMO Market: Therapeutic Area Estimates & Trend Analysis
6.1. Antibody CDMO Market, By Therapeutic Area: Segment Dashboard
6.2. Antibody CDMO Market, By Therapeutic Area: Movement Analysis
6.3. Antibody CDMO Market Estimates & Forecasts, By Therapeutic Area, 2018 – 2030
6.3.1. Oncology
6.3.1.1. Oncology Antibody CDMO Market 2018 to 2030 (USD Million)
6.3.2. Neurology
6.3.2.1. Neurology Antibody CDMO Market 2018 to 2030 (USD Million)
6.3.3. Cardiology
6.3.3.1. Cardiology Antibody CDMO Market 2018 to 2030 (USD Million)
6.3.4. Infectious Diseases
6.3.4.1. Infectious Diseases Antibody CDMO Market 2018 to 2030 (USD Million)
6.3.5. Immune-mediated Disorders
6.3.5.1. Immune-mediated Disorders Antibody CDMO Market 2018 to 2030 (USD Million)
6.3.6. Others
6.3.6.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)
Chapter 7. Antibody CDMO Market: End Use Estimates & Trend Analysis
7.1. Antibody CDMO Market, By End Use: Segment Dashboard
7.2. Antibody CDMO Market, By End Use: Movement Analysis
7.3. Antibody CDMO Market Estimates & Forecasts, By End Use, 2018 – 2030
7.3.1. Biopharmaceutical Companies
7.3.1.1. Biopharmaceutical Companies Antibody CDMO Market 2018 to 2030 (USD Million)
7.3.2. Research Laboratories
7.3.2.1. Research Laboratories Antibody CDMO Market 2018 to 2030 (USD Million)
7.3.3. Others
7.3.3.1. Others Antibody CDMO Market 2018 to 2030 (USD Million)
Chapter 8. Antibody CDMO Market: Regional Estimates & Trend Analysis
8.1. Regional Market Share Analysis, 2022 & 2030
8.2. Regional Market Dashboard
8.3. Global Regional Market Snapshot
8.4. North America
8.4.1. Market Estimates and Forecast, 2018 – 2030 (Revenue, USD Million)
8.4.2. U.S.
8.4.2.1. Key Country Dynamics
8.4.2.2. Competitive Scenario
8.4.2.3. Regulatory Framework
8.4.2.4. U.S. Market Estimates and Forecasts, 2018 – 2030
8.4.3. Canada
8.4.3.1. Key Country Dynamics
8.4.3.2. Competitive Scenario
8.4.3.3. Regulatory Framework
8.4.3.4. Canada Market Estimates and Forecasts, 2018 – 2030
8.5. Europe
8.5.1. UK
8.5.1.1. Key Country Dynamics
8.5.1.2. Competitive Scenario
8.5.1.3. Regulatory Framework
8.5.1.4. UK Market Estimates and Forecasts, 2018 – 2030
8.5.2. Germany
8.5.2.1. Key Country Dynamics
8.5.2.2. Competitive Scenario
8.5.2.3. Regulatory Framework
8.5.2.4. Germany Market Estimates and Forecasts, 2018 – 2030
8.5.3. France
8.5.3.1. Key Country Dynamics
8.5.3.2. Competitive Scenario
8.5.3.3. Regulatory Framework
8.5.3.4. France Market Estimates and Forecasts, 2018 – 2030
8.5.4. Italy
8.5.4.1. Key Country Dynamics
8.5.4.2. Competitive Scenario
8.5.4.3. Regulatory Framework
8.5.4.4. Italy Market Estimates and Forecasts, 2018 – 2030
8.5.5. Spain
8.5.5.1. Key Country Dynamics
8.5.5.2. Competitive Scenario
8.5.5.3. Regulatory Framework
8.5.5.4. Spain Market Estimates and Forecasts, 2018 – 2030
8.5.6. Denmark
8.5.6.1. Key Country Dynamics
8.5.6.2. Competitive Scenario
8.5.6.3. Regulatory Framework
8.5.6.4. Denmark Market Estimates and Forecasts, 2018 – 2030
8.5.7. Sweden
8.5.7.1. Key Country Dynamics
8.5.7.2. Competitive Scenario
8.5.7.3. Regulatory Framework
8.5.7.4. Sweden Market Estimates and Forecasts, 2018 – 2030
8.5.8. Norway
8.5.8.1. Key Country Dynamics
8.5.8.2. Competitive Scenario
8.5.8.3. Regulatory Framework
8.5.8.4. Norway Market Estimates and Forecasts, 2018 – 2030
8.6. Asia Pacific
8.6.1. Japan
8.6.1.1. Key Country Dynamics
8.6.1.2. Competitive Scenario
8.6.1.3. Regulatory Framework
8.6.1.4. Japan Market Estimates and Forecasts, 2018 – 2030
8.6.2. India
8.6.2.1. Key Country Dynamics
8.6.2.2. Competitive Scenario
8.6.2.3. Regulatory Framework
8.6.2.4. India Market Estimates and Forecasts, 2018 – 2030
8.6.3. China
8.6.3.1. Key Country Dynamics
8.6.3.2. Competitive Scenario
8.6.3.3. Regulatory Framework
8.6.3.4. China Market Estimates and Forecasts, 2018 – 2030
8.6.4. South Korea
8.6.4.1. Key Country Dynamics
8.6.4.2. Competitive Scenario
8.6.4.3. Regulatory Framework
8.6.4.4. South Korea Market Estimates and Forecasts, 2018 – 2030
8.6.5. Australia
8.6.5.1. Key Country Dynamics
8.6.5.2. Competitive Scenario
8.6.5.3. Regulatory Framework
8.6.5.4. Australia Market Estimates and Forecasts, 2018 – 2030
8.6.6. Thailand
8.6.6.1. Key Country Dynamics
8.6.6.2. Competitive Scenario
8.6.6.3. Regulatory Framework
8.6.6.4. Thailand Market Estimates and Forecasts, 2018 – 2030
8.7. Latin America
8.7.1. Brazil
8.7.1.1. Key Country Dynamics
8.7.1.2. Competitive Scenario
8.7.1.3. Regulatory Framework
8.7.1.4. Brazil Market Estimates and Forecasts, 2018 – 2030
8.7.2. Mexico
8.7.2.1. Key Country Dynamics
8.7.2.2. Competitive Scenario
8.7.2.3. Regulatory Framework
8.7.2.4. Mexico Market Estimates and Forecasts, 2018 – 2030
8.7.3. Argentina
8.7.3.1. Key Country Dynamics
8.7.3.2. Competitive Scenario
8.7.3.3. Regulatory Framework
8.7.3.4. Argentina Market Estimates and Forecasts, 2018 – 2030
8.8. MEA
8.8.1. South Africa
8.8.1.1. Key Country Dynamics
8.8.1.2. Competitive Scenario
8.8.1.3. Regulatory Framework
8.8.1.4. South Africa Market Estimates and Forecasts, 2018 – 2030
8.8.2. Saudi Arabia
8.8.2.1. Key Country Dynamics
8.8.2.2. Competitive Scenario
8.8.2.3. Regulatory Framework
8.8.2.4. Saudi Arabia Market Estimates and Forecasts, 2018 – 2030
8.8.3. UAE
8.8.3.1. Key Country Dynamics
8.8.3.2. Competitive Scenario
8.8.3.3. Regulatory Framework
8.8.3.4. UAE Market Estimates and Forecasts, 2018 – 2030
8.8.4. Kuwait
8.8.4.1. Key Country Dynamics
8.8.4.2. Competitive Scenario
8.8.4.3. Regulatory Framework
8.8.4.4. Kuwait Market Estimates and Forecasts, 2018 – 2030
Chapter 9. Competitive Landscape
9.1. Market Participant Categorization
9.1.1. Innovators
9.1.2. Market Leaders
9.1.3. Emerging Players
9.1.4. Company Market Share Analysis, 2022
9.2. Company Profiles
9.2.1. Lonza
9.2.1.1. Company Overview
9.2.1.2. Financial Performance
9.2.1.3. Service Benchmarking
9.2.1.4. Strategic Initiatives
9.2.2. Catalent, Inc
9.2.2.1. Company Overview
9.2.2.2. Financial Performance
9.2.2.3. Service Benchmarking
9.2.2.4. Strategic Initiatives
9.2.3. Samsung Biologics
9.2.3.1. Company Overview
9.2.3.2. Financial Performance
9.2.3.3. Service Benchmarking
9.2.3.4. Strategic Initiatives
9.2.4. WuXi Biologics
9.2.4.1. Company Overview
9.2.4.2. Financial Performance
9.2.4.3. Service Benchmarking
9.2.4.4. Strategic Initiatives
9.2.5. AGC Biologics
9.2.5.1. Company Overview
9.2.5.2. Financial Performance
9.2.5.3. Service Benchmarking
9.2.5.4. Strategic Initiatives
9.2.6. AbbVie Inc.
9.2.6.1. Company Overview
9.2.6.2. Financial Performance
9.2.6.3. Service Benchmarking
9.2.6.4. Strategic Initiatives
9.2.7. Boehringer Ingelheim International GmbH
9.2.7.1. Company Overview
9.2.7.2. Financial Performance
9.2.7.3. Service Benchmarking
9.2.7.4. Strategic Initiatives
9.2.8. Charles River Laboratories
9.2.8.1. Company Overview
9.2.8.2. Financial Performance
9.2.8.3. Service Benchmarking
9.2.8.4. Strategic Initiatives
9.2.9. FUJIFILM Holdings Corporation
9.2.9.1. Company Overview
9.2.9.2. Financial Performance
9.2.9.3. Service Benchmarking
9.2.9.4. Strategic Initiatives
9.2.10. mAbxience
9.2.10.1. Company Overview
9.2.10.2. Financial Performance
9.2.10.3. Service Benchmarking
9.2.10.4. Strategic Initiatives

List of Tables

Table 1 List of secondary sources
Table 2 List of Abbreviations
Table 3 North America Antibody CDMO market, by region, 2018 - 2030 (USD Million)
Table 4 North America Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 5 North America Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 6 North America Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 7 North America Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 8 U.S. Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 9 U.S. Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 10 U.S. Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 11 U.S. Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 12 Canada Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 13 Canada Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 14 Canada Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 15 Canada Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 16 Europe Antibody CDMO market, by region, 2018 - 2030 (USD Million)
Table 17 Europe Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 18 Europe Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 19 Europe Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 20 Europe Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 21 UK Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 22 UK Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 23 UK Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 24 UK Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 25 Germany Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 26 Germany Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 27 Germany Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 28 Germany Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 29 France Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 30 France Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 31 France Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 32 France Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 33 Italy Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 34 Italy Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 35 Italy Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 36 Italy Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 37 Spain Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 38 Spain Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 39 Spain Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 40 Spain Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 41 Denmark Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 42 Denmark Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 43 Denmark Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 44 Denmark Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 45 Sweden Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 46 Sweden Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 47 Sweden Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 48 Sweden Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 49 Norway Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 50 Norway Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 51 Norway Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 52 Norway Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 53 Asia Pacific Antibody CDMO market, by region, 2018 - 2030 (USD Million)
Table 54 Asia Pacific Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 55 Asia Pacific Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 56 Asia Pacific Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 57 Asia Pacific Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 58 China Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 59 China Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 60 China Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 61 China Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 62 Japan Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 63 Japan Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 64 Japan Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 65 Japan Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 66 India Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 67 India Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 68 India Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 69 India Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 70 Australia Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 71 Australia Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 72 Australia Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 73 Australia Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 74 South Korea Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 75 South Korea Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 76 South Korea Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 77 South Korea Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 78 Thailand Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 79 Thailand Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 80 Thailand Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 81 Thailand Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 82 Latin America Antibody CDMO market, by region, 2018 - 2030 (USD Million)
Table 83 Latin America Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 84 Latin America Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 85 Latin America Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 86 Latin America Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 87 Brazil Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 88 Brazil Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 89 Brazil Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 90 Brazil Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 91 Mexico Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 92 Mexico Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 93 Mexico Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 94 Mexico Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 95 Argentina Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 96 Argentina Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 97 Argentina Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 98 Argentina Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 99 Middle East and Africa Antibody CDMO market, by region, 2018 - 2030 (USD Million)
Table 100 Middle East and Africa Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 101 Middle East and Africa Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 102 Middle East and Africa Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 103 Middle East & Africa Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 104 South Africa Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 105 South Africa Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 106 South Africa Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 107 South Africa Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 108 Saudi Arabia Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 109 Saudi Arabia Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 110 Saudi Arabia Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 111 Saudi Arabia Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 112 UAE Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 113 UAE Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 114 UAE Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 115 UAE Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)
Table 116 Kuwait Antibody CDMO market, by Source, 2018 - 2030 (USD Million)
Table 117 Kuwait Antibody CDMO market, by Product, 2018 - 2030 (USD Million)
Table 118 Kuwait Antibody CDMO market, by Therapeutic Area, 2018 - 2030 (USD Million)
Table 119 Kuwait Antibody CDMO market, by End Use, 2018 - 2030 (USD Million)

List of Figures

Fig. 1 Market research process
Fig. 2 Information procurement
Fig. 3 Market research approaches
Fig. 4 QFD modelling for market share assessment
Fig. 5 Market formulation & validation
Fig. 6 Commodity flow analysis
Fig. 7 Primary research pattern
Fig. 8 Primary interviews in North America
Fig. 9 Primary interviews in Europe
Fig. 10 Primary interviews in Asia Pacific
Fig. 11 Primary interviews in Latin America
Fig. 12 Primary interviews in MEA
Fig. 13 Market Snapshot
Fig. 14 Segment Snapshot
Fig. 15 Competitive Landscape Snapshot
Fig. 16 Antibody CDMO market segmentation
Fig. 17 Parent market outlook (2022)
Fig. 18 Related/ancillary market outlook (2022)
Fig. 19 Market driver relevance analysis (Current & future impact)
Fig. 20 Market restraint relevance analysis (Current & future impact)
Fig. 21 Porter’s five forces analysis
Fig. 22 SWOT analysis, by a factor (political & legal, economic and technological)
Fig. 23 Antibody CDMO Market Product outlook: Segment dashboard
Fig. 24 Antibody CDMO :Product movement analysis
Fig. 25 Monoclonal Antibodies market, 2018 - 2030 (USD Million)
Fig. 26 Polyclonal Antibodies market, 2018 - 2030 (USD Million)
Fig. 27 Others Antibodies market, 2018 - 2030 (USD Million)
Fig. 28 Antibody CDMO Market Source outlook: Segment dashboard
Fig. 29 Antibody CDMO : Source type movement analysis
Fig. 30 Mammalian market, 2018 - 2030 (USD Million)
Fig. 31 Microbial market, 2018 - 2030 (USD Million)
Fig. 32 Antibody CDMO market Therapeutic Area outlook: Segment dashboard
Fig. 33 Antibody CDMO market: Therapeutic Area movement analysis
Fig. 34 Oncology market, 2018 - 2030 (USD Million)
Fig. 35 Neurology market, 2018 - 2030 (USD Million)
Fig. 36 Cardiology market, 2018 - 2030 (USD Million)
Fig. 37 Infectious Diseases market, 2018 - 2030 (USD Million)
Fig. 38 Immune-mediated Disorders market, 2018 - 2030 (USD Million)
Fig. 39 Others market, 2018 - 2030 (USD Million)
Fig. 40 Regional marketplace: Segment dashboard
Fig. 41 Regional outlook, 2022 & 2030
Fig. 42 North America market, 2018 - 2030 (USD Million)
Fig. 43 U.S. market, 2018 - 2030 (USD Million)
Fig. 44 Canada market, 2018 - 2030 (USD Million)
Fig. 45 Europe market, 2018 - 2030 (USD Million)
Fig. 46 Germany market, 2018 - 2030 (USD Million)
Fig. 47 UK market, 2018 - 2030 (USD Million)
Fig. 48 France market, 2018 - 2030 (USD Million)
Fig. 49 Italy market, 2018 - 2030 (USD Million)
Fig. 50 Spain market, 2018 - 2030 (USD Million)
Fig. 51 Denmark market, 2018 - 2030(USD Million)
Fig. 52 Sweden market, 2018 - 2030 (USD Million)
Fig. 53 Norway market, 2018 - 2030 (USD Million)
Fig. 54 Asia Pacific market, 2018 - 2030 (USD Million)
Fig. 55 China market, 2018 - 2030 (USD Million)
Fig. 56 Japan market, 2018 - 2030 (USD Million)
Fig. 57 India market, 2018 - 2030 (USD Million)
Fig. 58 Australia market, 2018 - 2030 (USD Million)
Fig. 59 Thailand market, 2018 - 2030 (USD Million)
Fig. 60 South Korea market, 2018 - 2030 (USD Million)
Fig. 61 Latin America market, 2018 - 2030 (USD Million)
Fig. 62 Brazil market, 2018 - 2030 (USD Million)
Fig. 63 Mexico market, 2018 - 2030 (USD Million)
Fig. 64 Argentina market, 2018 - 2030 (USD Million)
Fig. 65 Middle East & Africa market, 2018 - 2030 (USD Million)
Fig. 66 South Africa market, 2018 - 2030 (USD Million)
Fig. 67 Saudi Arabia market, 2018 - 2030 (USD Million)
Fig. 68 UAE market, 2018 - 2030 (USD Million)
Fig. 69 Kuwait market, 2018 - 2030 (USD Million)

★調査レポート[世界の抗体受託開発・製造機関市場2023-2030：製品別、供給源別、治療領域別（腫瘍学、神経学、心臓病学）、エンドユーザー別、地域別] (コード：GRV23NOV036)販売に関する免責事項を必ずご確認ください。
★調査レポート[世界の抗体受託開発・製造機関市場2023-2030：製品別、供給源別、治療領域別（腫瘍学、神経学、心臓病学）、エンドユーザー別、地域別]についてメールでお問い合わせ
◆関連市場調査レポート◆
  • 世界のインシリコ臨床試験市場（～2030年）：治療領域別（腫瘍学、心臓病学、糖尿病、感染症、神経、血液、皮膚科、その他）、フェーズ別（フェーズI、フェーズII、フェーズIII、フェーズIV）、用途別、エンドユーザー別、地域別
  • 世界のヘパリン市場2024-2030：タイプ別、投与経路別、用途別、エンドユーザー別（外来患者、入院患者）、供給源別、地域別
  • 世界のプロテイナーゼK市場（2023-2030）：形態別（粉末、液体）、治療領域別（感染症、神経、腫瘍、循環器）、用途別、エンドユーザー別、地域別
  • 世界のスクアラン市場2024-2030：供給源別（動物性、植物性、合成）、エンドユーザー別（医薬品、栄養補助食品）、地域別
  • 世界の超音波装置市場2024-2030：用途別（心臓病学、放射線学）、携帯性別（ハンドヘルド、コンパクト）、最終用途別（病院、画像診断センター）、製品別（治療、診断）
  • 世界の建築用照明市場2023-2030：コンポーネント別（バラスト、ランプ）、用途別（屋内、屋外）、供給源別、エンドユーザー別（商業、住宅、産業）、地域別
  • 世界のアミノ酸市場2024-2030：種類別（必須、非必須）、供給源別（植物由来、動物由来）、グレード別（食品、飼料）、エンドユーザー別（食品＆飲料、栄養補助食品）、地域別
  • 世界のアデノ随伴ウイルス（AAV）ベクター製造市場2023-2030：事業規模別（臨床、商業）、方法別、用途別、治療領域別、地域別
  • 世界のアミノ酸市場2023-2030：タイプ別、供給源別（植物由来、動物由来）、グレード別、エンドユーザー別（食品・飲料、栄養補助食品）

    • ◆H&Iグローバルリサーチのお客様（例）◆